The first-in-human clinical trial assessing the safety and tolerability of Miltuximab (MIL-38) — a radiolabeled antibody designed to image prostate, bladder, and pancreatic cancer — is proceeding to its second part, according to Minomic International.
https://prostatecancernewstoday.com/2017/07/13/clinical-trial-miltuximab-in-prostate-other-cancers-gets-approval-to-enroll-more-patients/

The first-in-human clinical trial assessing the safety and tolerability of Miltuximab (MIL-38) — a radiolabeled antibody designed to image prostate, bladder, and pancreatic cancer — is proceeding to its second part, according to Minomic International.
https://prostatecancernewstoday.com/2017/07/13/clinical-trial-miltuximab-in-prostate-other-cancers-gets-approval-to-enroll-more-patients/